Pre-Clinical Laboratory Services
|Pipeline Code||Therapeutic Area||Design||Chemistry||Pre-Clinical||Clinical||Collabration/Licensing||Regulatory|
|CB-ND-002||Nephropathic Cystinosis||IND Filling 2020|
Cellomatics BioSciences Ltd announced its collaboration with Krisani Biosciences to advance a novel molecular conjugate prodrug of cysteamine and eicosapentaenoic acid (EPA) for the therapeutic management of nephropathic cystinosis. This novel molecular conjugate prodrug of cysteamine and eicosapentaenoic acid (EPA) is patented in the United States.
Cellomatics BioSciences is leading the development of CB-ND-002 portfolio of cysteamine and eicosapentaenoic acid (EPA) conjugates/salts from non-clinical studies to Investigational New Drug Application filing with FDA. Cellomatics BioSciences has exclusive rights to develop the CB-ND-002 portfolio for global market. The collaboration also will advance the IND approved molecules through clinical stage studies, regulatory approval and commercialization of therapy for Nephropathic cystinosis.
[ More Info... ]